US20050142627A1 - Method of lipid assay and reagent for use therein - Google Patents

Method of lipid assay and reagent for use therein Download PDF

Info

Publication number
US20050142627A1
US20050142627A1 US11/066,168 US6616805A US2005142627A1 US 20050142627 A1 US20050142627 A1 US 20050142627A1 US 6616805 A US6616805 A US 6616805A US 2005142627 A1 US2005142627 A1 US 2005142627A1
Authority
US
United States
Prior art keywords
reagent
organic silicon
silicone
lipid
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/066,168
Inventor
Mitsuaki Yamamoto
Shoko Yamamoto
Mitsuhiro Nakamura
Kazunori Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pure Chemicals Co Ltd
Original Assignee
Daiichi Pure Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/066,168 priority Critical patent/US20050142627A1/en
Application filed by Daiichi Pure Chemicals Co Ltd filed Critical Daiichi Pure Chemicals Co Ltd
Publication of US20050142627A1 publication Critical patent/US20050142627A1/en
Priority to US12/047,357 priority patent/US20080166746A1/en
Priority to US12/969,900 priority patent/US20110287460A1/en
Priority to US13/198,020 priority patent/US20120178117A1/en
Priority to US13/738,449 priority patent/US20130164768A1/en
Priority to US13/763,125 priority patent/US20130210044A1/en
Priority to US14/067,216 priority patent/US20140051102A1/en
Priority to US14/287,786 priority patent/US20140287444A1/en
Priority to US15/047,421 priority patent/US20160209434A1/en
Priority to US15/720,274 priority patent/US20180038878A1/en
Priority to US16/409,965 priority patent/US20190331700A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/61—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving triglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Definitions

  • the present invention relates to a method of separately assaying lipid components in specific lipoprotein fractions efficiently by a simple procedure using a small amount of sample.
  • the present invention also relates to a reagent used for the method.
  • LDL very low density lipoprotein
  • LDL low density lipoprotein
  • HDL high density lipoprotein
  • a method of determining the total amount of specific lipid contained in all lipoproteins such as total cholesterol and total triglycerides and a method of determining cholesterols in specific lipoproteins such as LDL, HDL, and the like can be given.
  • the former method is based on the combination of an enzyme for the lipid component to be assayed and conditions enabling the reaction of the lipid component with the enzyme without regard to the type of lipoproteins (for example, a surfactant with low lipoprotein selectivity such as Triton X-100).
  • the method enables assaying the lipid components to be assayed in all lipoproteins.
  • the latter method is based on the combination of an enzyme for the lipid component to be assayed and specific conditions enabling the enzyme to react only with the lipid component to be assayed in specific lipoproteins.
  • the method enables the assay of the lipid components to be assayed in the specific lipoprotein fractions.
  • Such methods include a method of utilizing the different reaction times of bile acid for each lipoprotein fraction in the determination of HDL cholesterols (Japanese Patent Publication No. 016720/1994), a method of reacting the lipoproteins to be assayed with an enzyme under the condition that lipoproteins not to be assayed stay aggregated (Japanese Patent Application Laid-open Publication No. 242110/1994), a method of using a sugar compound (Japanese Patent No. 2653755), a method of using a modification enzyme (Japanese Patent No.
  • an object of the present invention is to provide a method of assaying lipid components in blood and the like using a substance capable of establishing the specific conditions under the direct method while neither affecting assay precision nor damaging assay instruments, and also satisfying other conditions such as easy availability.
  • the inventors of the present invention have conducted extensive studies to achieve the above object and completed the present invention with the following method.
  • assaying the lipid components in specific lipoproteins to be assayed such as HDL cholesterols
  • the HDL cholesterols alone can be selectively assayed with specificity even in the absence of precipitation agents and modification enzymes if an organic silicon compound is added to the reagent, and the enzyme having the cholesterol as a substrate is mixed with the sample to be assayed.
  • the present invention provides a method of lipid assay characterized by the assay conducted in the presence of an organic silicon compound and a reagent used for the assay.
  • FIG. 1 is a chart for showing the correlation between the results of assaying HDL cholesterol in a blood serum sample obtained by the method of the present invention shown in Example 2 or the control method using a reagent not containing an organic silicon compound of the present invention and the results obtained by the precipitation method, wherein A shows the correlation for the control method and B shows the correlation for the method of the present invention.
  • FIG. 2 is a chart for showing the correlation between the results of assaying HDL cholesterol in a blood serum sample obtained by the method of the present invention shown in Example 3A or 3B or the control method using a reagent not containing the organic silicon compound of the present invention and the results obtained by the precipitation method, wherein A, B, and C show the correlations for the control method, the method of Example 3A, and the method of Example 3B respectively.
  • FIG. 3 is a chart for showing the correlation between the results of assaying HDL cholesterol in a blood serum sample obtained by the method of the present invention shown in Example 4 or the control method using a reagent not containing an organic silicon compound of the present invention and the results obtained by the precipitation method, wherein A shows the correlation for the control method and B shows the correlation for the method of the present invention.
  • the method of the present invention comprises assaying lipid using a known reagent for assaying lipids in the presence of an organic silicon compound.
  • Silicones and their derivatives can be given as the organic silicon compound in the present invention.
  • the silicones are the polymers which have organic groups such as an alkyl group or aryl group.
  • the polymers comprise —(Si—O) n —, which is generally called polysiloxane, the recurrence 6 structure of siloxane unit which consists of a silicon atom bonded with an oxygen atom.
  • Properties of silicones differ according to the molecular structure. Viscosity, volatility, and other properties vary according to the degree of polymerization, types of side chains, the degree of crosslinking, and the like. There are liquid silicones, greasy silicones, rubbery silicones, and resinous silicones.
  • the modified silicone oil is the silicone oil to which an organic group is added. According to the added organic group, the modified silicone oil is classified as an amino modified silicone oil, epoxy modified silicone oil, carboxyl modified silicone oil, polyether modified silicone oil, alkyl modified silicone oil, or the like. According to the structure, the modified silicone oil is classified as a side chain silicone oil, both terminal silicone oil, one terminal silicone oil, and side chain both terminal silicone oil.
  • Manufacturers publish catalogues describing properties and the like of their organic silicon products. Specific organic silicon compounds to be used may be selected by referring to these catalogues.
  • the organic silicon compound of the present invention may be either added simultaneously with the sample and the reagent for assaying the target lipid or mixed with the sample before adding the reagent for assaying the target lipid.
  • the target lipid may be assayed by first preparing a mixture of the sample and a part of the reagent for assaying the target lipid and adding to the mixture the remaining portion of the reagent containing the organic silicon compound of the present invention.
  • the amount of the organic silicon compound used for the sample in the present invention varies according to the type of the lipid to be assayed, the properties of the sample, the type of the reagent used, the presence or absence of the later-described surfactant or glycerol, or the amount of the surfactant or glycerol, and the like. Although optimum conditions should be selected by experiment, generally used amount of the organic silicon compound is about 0.0001-5 mass % (hereinafter simply referred to as “%”), and more preferably about 0.001-5%.
  • the organic silicon compound of the present invention can enhance the properties of these surfactants.
  • any of anionic surfactants, nonionic surfactants, cationic surfactants, and ampholytic surfactants may be used without specific limitations.
  • examples include alkyl ether carboxylates, salts of N-acylamino acid, alkyl phosphates, N-acyl taurates, sulfonates, alkyl sulfates, polyoxyethylene alkyl ether sulfates, acetic acid betaines, imidazolines, alkyl ammonium salts, amide amines, polyhydric alcohol fatty acid esters, alkyl glyceryl ethers and their fatty acid esters, propylene glycol fatty acid esters, glycerides, polyglycerides, polyoxyethylene glycerides, sorbitan fatty acid esters, polyoxysorbitan fatty acid esters, polyoxyethylene sorbit fatty acid esters, polyoxyethylene lanolins, polyoxyethylene lanolin alcohols, polyoxyethylene bee
  • surfactants may be added to the assay system either individually or in combination of two or more.
  • the combination and amount of these surfactants vary according to the type of silicones and their derivatives, the type of surfactant used, and the like. Although optimum conditions should be selected by experiment, generally used concentration of the surfactant in the assay system is about 0.0001-5%, and more preferably about 0.001-5%.
  • polymer emulsifying agents such as an acrylic acid-alkyl methacrylate copolymer and carboxy vinyl polymer
  • organic solvents such as ethanol, silicones and their derivatives not adversely affecting the assay specificity, and the like can be used in adjusting the water solubility.
  • the lipid to be assayed by the method of the present invention may be any lipid present in the living body, and particularly preferable lipids are those forming lipoproteins such as cholesterols, triglycerides, and phospholipids.
  • Any enzyme having the target lipid as the substrate can be used in assaying the lipid in the method of the present invention.
  • Enzymes commonly used for assaying cholesterols, triglycerides, and phospholipids described in Outline of Clinical Diagnosis Method, the 30 th edition, (Kanehara and Co., Ltd., 1993), for example, can be used in the present invention and are included in the scope of the present invention.
  • enzymes commonly used for assaying cholesterols such as cholesterol dehydrogenase, cholesterol oxidase, and cholesterol esterase can be used without a limitation. These enzymes may be those originating from microorganisms, animals, or plants or may be those prepared by a genetic engineering technique. Either chemically modified or unmodified enzymes can be used.
  • These enzymes may be optionally used in combination with a coenzyme, a detecting enzyme or dyeing agent, or the like.
  • a coenzyme nicotine amide adenine dinucleotide and the like can be given.
  • detecting enzyme peroxidase and the like can be given.
  • dyeing agent Trinder reagent, aminoantipyrine, and the like can be given.
  • the detecting enzymes may be used either individually or in combination of two or more.
  • the amount used differs according to the enzymes.
  • the enzyme in the amount of 0.001-100 unit/mL, and preferably 0.1-100 unit/mL, is used.
  • the method of the present invention can be advantageously carried out by using a reagent for assaying lipid prepared by appropriately formulating the above-described organic silicon compound, enzyme for assaying lipid, dyeing agent, coenzyme, and the like.
  • reagents having affinity with specific lipoproteins including other enzymes such as catalase, salts, pH adjusting buffering agents, surfactants, antiseptic agents, proteins such as albumin, antibodies, antibiotics, saponins, lectins, and polyanions, can be added to the extent that the assay specificity is not adversely affected and the specific lipoproteins are not aggregated.
  • any buffering agent such as Good's. buffer, phosphoric acid, Tris buffer, and phthalate may be used inasmuch as the buffering agent can establish buffering conditions of pH of the reaction solution in the range of 4-10.
  • the amount in the range of 0.0005-2 mol/L, and preferably of 0.01-1 mol/L, is applicable. In practice, optimum conditions should be selected by experiment in due consideration to the properties of the enzyme used, other components contained in the reagent, and the like.
  • the effect of the present invention was confirmed using HDL and LDL fractions prepared by ultracentrifugation as the samples.
  • the reagent with the following formulation was used for assaying cholesterols in the HDL and LDL fractions.
  • Hitachi 7170 automatic analyzer was used. 240 ⁇ L of the first reagent was added to 2.4 ⁇ L of the sample. Five minutes later, 80 ⁇ L of the second reagent was added. Absorbance at a wavelength of 600 nm was measured immediately before the addition of the second reagent and 5 minutes thereafter. The difference of the two measurements was regarded as the absorbance of the sample. As a control, a reagent which contains 1% Triton X-100 having low lipoprotein selectivity instead of the organic silicon compound of the present invention was used as the second reagent.
  • Relative sample absorbances measured using reagents containing a different organic silicon compound for each as the second reagents were determined assuming the absorbance of the sample using the second reagent containing the Triton X-100 as 100.
  • the ratio of the relative sample absorbance for LDL to the relative sample absorbance for HDL was calculated. The results are shown in Table 1.
  • the LDL/HDL ratio of the relative absorbance when measured by using the second reagents containing the organic silicon compounds of the present invention was in the range of 0.04-0.5.
  • the results indicate that the organic silicon compound of the present invention established special conditions under which the reaction between cholesterols in HDL and enzymes is predominant over the reaction between cholesterols in LDL and enzymes.
  • Hitachi 7170 automatic analyzer was used. 240 ⁇ L of the first reagent was added to 2.4 ⁇ L of the sample. Five minutes later, 80 ⁇ L of the second reagent was added. Absorbance at 600 nm wavelength was measured immediately before the addition of the second reagent and 5 minutes after the addition of the second reagent, to determine the HDL cholesterol concentration from the difference in the absorbance values (Two point method). A control serum with a known concentration was used as a calibration substance. As a control, a reagent not containing the organic silicon compound of the present invention was used as the second reagent.
  • the HDL cholesterol concentration in the serum sample was determined using a commercially available precipitation reagent kit (HDL-C. 2 kit manufactured by Daiichi Pure Chemicals Co., Ltd.).
  • the correlation coefficients and regression formula were compared, taking the value of the reagent in the precipitation method as X axis and the measured value in Examples as Y axis.
  • the results are shown in Table 2 and FIG. 1 .
  • the results measured by using the second reagent containing the organic silicon compound of the present invention exhibited improved slope and intercept as compared with the results measured by using the second reagent not containing the organic silicon compound of the present invention. This indicates that the organic silicon compound of the present invention established specific conditions under which the reaction between cholesterols in HDL and enzymes is predominant over the reaction between cholesterols in LDL and enzymes, whereby the characteristics of the surfactant having lipoprotein selectivity was further improved.
  • Example 3A The effect of the present invention was confirmed in the same condition as in Example 2 except that 26 serum samples containing lipoproteins were used as the samples and NET-SG-60A (Example 3A) or NET-SG-60C (Example 3B) (both at a concentration of 0.05%, manufactured by Nihon Surfactant Kogyo KK.) was used as the organic silicon compound of the present invention in the second reagent.
  • NET-SG-60A Example 3A
  • NET-SG-60C Example 3B
  • the results measured by using the second reagent containing the organic silicon compound of the present invention exhibited improved slope and intercept as compared with the results measured by using the second reagent not containing the organic silicon compound of the present invention. This indicates that the organic silicon compound of the present invention established specific conditions under which the reaction between cholesterols in HDL and enzymes is predominant over the reaction between cholesterols in LDL and enzymes, whereby the characteristics of the surfactant having lipoprotein selectivity was further improved.
  • Example 2 The effect of the present invention was confirmed in the same condition as in Example 2 except that 30 serum samples containing lipoproteins were used as the samples and KF-700 (0.08%, manufactured by Shin-Etsu Chemical Co., Ltd.) was used as the organic silicon compound of the present invention in the second reagent.
  • KF-700 0.08%, manufactured by Shin-Etsu Chemical Co., Ltd.
  • the results measured by using the second reagent containing the organic silicon compound of the present invention exhibited improved slope and intercept as compared with the results measured by using the second reagent not containing the organic silicon compound of the present invention. This indicates that the organic silicon compound of the present invention established specific conditions under which the reaction between cholesterols in HDL and enzymes is predominant over the reaction between cholesterols in LDL and enzymes, whereby the characteristics of the surfactant having lipoprotein selectivity was further improved.
  • Example 5 The effect of the present invention was confirmed in the same condition as in Example 2 except that 20 serum samples containing lipoproteins were used as the samples and the organic silicon compounds shown in Table 5 were used in the second reagent.
  • Table 5 the organic silicon compounds of Examples 5A-5D were used for formulating the second reagent after dissolving these compounds in ethanol to a concentration of 10%.
  • the organic silicon compounds of Examples 5E and 5F were used for formulating the second reagent after dissolving and mixing these compounds in ethanol together with SH8400 (modified silicone oil manufactured by Dow Corning Toray Silicone Co., Ltd.) to a respective concentration of 10%.
  • SH8400 modified silicone oil manufactured by Dow Corning Toray Silicone Co., Ltd.
  • the results measured by using the second reagent containing the organic silicon compound of the present invention exhibited particularly improved intercept as compared with the results measured by using the second reagent not containing the organic silicon compound of the present invention. This indicates that the organic silicon compound of the present invention established specific conditions under which the reaction with cholesterols in HDL is predominant over the reaction between cholesterols in LDL and enzymes, whereby the characteristics of the surfactant having lipoprotein selectivity was further improved.
  • Lipids in specific fractions can be quantitatively determined efficiently by a simple procedure without requiring a pretreatment such as centrifugation by using the method of the present invention.
  • the method allows specific determination by a simple method using a small amount of sample, the method can be applied to various types of automatic analyzers. The method is thus extremely useful in the field of clinical diagnosis.
  • the high lipoprotein selectivity particularly improves the intercept and slope, providing an advantage of minute lipoprotein selectivity control.

Abstract

A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a method of separately assaying lipid components in specific lipoprotein fractions efficiently by a simple procedure using a small amount of sample. The present invention also relates to a reagent used for the method.
    • DESCRIPTION OF BACKGROUND ART
  • Cholesterols, triglycerides, and phospholipids which are major lipids in the living body are combined with apoproteins to form lipoproteins in blood. The lipoproteins are grouped into chylomicron, very low density lipoprotein (VLDL), low density lipoprotein (LDL), high density lipoprotein (HDL), and the like according to their physical properties. Among these lipoproteins, it is known that LDL is a causative factor for arteriosclerosis, whereas HDL exhibits an anti-arteriosclerosis effect.
  • Total cholesterols and total triglycerides in blood have been assayed for the purpose of preventing ischemic heart diseases or evaluating the effects of treatments for such diseases. Epidemiological studies have proved that the cholesterol level in LDL has a positive correlation with the frequency of arteriosclerosis occurrence, whereas the cholesterol level in HDL has a negative correlation with the frequency of arteriosclerosis occurrence. Importance of knowing fluctuations in each lipoprotein fraction such as LDL and HDL has been understood. Nowadays, apoprotein B and apoprotein A-I, which are protein components forming each lipoprotein, or cholesterol in each lipoprotein fraction is assayed.
  • As mentioned above, as the method of assaying lipids components in blood, a method of determining the total amount of specific lipid contained in all lipoproteins such as total cholesterol and total triglycerides and a method of determining cholesterols in specific lipoproteins such as LDL, HDL, and the like can be given.
  • Of these, the former method is based on the combination of an enzyme for the lipid component to be assayed and conditions enabling the reaction of the lipid component with the enzyme without regard to the type of lipoproteins (for example, a surfactant with low lipoprotein selectivity such as Triton X-100). The method enables assaying the lipid components to be assayed in all lipoproteins.
  • The latter method, on the other hand, is based on the combination of an enzyme for the lipid component to be assayed and specific conditions enabling the enzyme to react only with the lipid component to be assayed in specific lipoproteins. The method enables the assay of the lipid components to be assayed in the specific lipoprotein fractions.
  • These specific conditions have been conventionally established by a method of isolating the lipoproteins to be assayed from a sample by ultracentrifugation, electrophoresis, gel filtration, precipitation using a precipitation agent (precipitation method), or the like (the method is hereinafter referred to as “fractionation method”).
  • In recent years, a number of methods for establishing specific conditions without using the fractionation method (hereinafter referred to as “direct methods”) have been developed. Such methods include a method of utilizing the different reaction times of bile acid for each lipoprotein fraction in the determination of HDL cholesterols (Japanese Patent Publication No. 016720/1994), a method of reacting the lipoproteins to be assayed with an enzyme under the condition that lipoproteins not to be assayed stay aggregated (Japanese Patent Application Laid-open Publication No. 242110/1994), a method of using a sugar compound (Japanese Patent No. 2653755), a method of using a modification enzyme (Japanese Patent No. 2600065), a method of using a surfactant which does not dissolve lipoproteins (Japanese Patent No. 2799835), a method of removing cholesterols in lipoproteins not to be assayed by a previous enzyme reaction (Japanese Patent Application Laid-open Publication No. 000299/1997), a method of using carrageenan (Japanese Patent Application Laid-open Publication No. 121895/1997), a method of using a surfactant having lipoprotein selectivity (Japanese Patent Application Laid-open Publication No. 056395/1999), a method of using Calixarene (WO 98/59068), and a method of using a phosphorus compound (Japanese Patent Application Laid-open Publication No. 116400/2000)
  • Some of these direct methods are used in practice in daily clinical tests due to their simple procedures as compared with the precipitation method involving complicated procedures. However, even the direct methods which have been put into practice have problems. For example, the method of adding a precipitation agent to the reagent has problems: interference of the aggregates on assay precision and a damage to measuring equipment such as clogged flow passages with the products produced from reaction of the precipitation agent with an alkaline detergent for washing measuring equipment. As for a method of using a modification enzyme, there are problems such as process control in enzyme modification procedures (quality control) and cost increase.
  • Accordingly, an object of the present invention is to provide a method of assaying lipid components in blood and the like using a substance capable of establishing the specific conditions under the direct method while neither affecting assay precision nor damaging assay instruments, and also satisfying other conditions such as easy availability.
    • DISCLOSURE OF THE INVENTION
  • The inventors of the present invention have conducted extensive studies to achieve the above object and completed the present invention with the following method. As for assaying the lipid components in specific lipoproteins to be assayed such as HDL cholesterols, the HDL cholesterols alone can be selectively assayed with specificity even in the absence of precipitation agents and modification enzymes if an organic silicon compound is added to the reagent, and the enzyme having the cholesterol as a substrate is mixed with the sample to be assayed.
  • Specifically, the present invention provides a method of lipid assay characterized by the assay conducted in the presence of an organic silicon compound and a reagent used for the assay.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a chart for showing the correlation between the results of assaying HDL cholesterol in a blood serum sample obtained by the method of the present invention shown in Example 2 or the control method using a reagent not containing an organic silicon compound of the present invention and the results obtained by the precipitation method, wherein A shows the correlation for the control method and B shows the correlation for the method of the present invention.
  • FIG. 2 is a chart for showing the correlation between the results of assaying HDL cholesterol in a blood serum sample obtained by the method of the present invention shown in Example 3A or 3B or the control method using a reagent not containing the organic silicon compound of the present invention and the results obtained by the precipitation method, wherein A, B, and C show the correlations for the control method, the method of Example 3A, and the method of Example 3B respectively.
  • FIG. 3 is a chart for showing the correlation between the results of assaying HDL cholesterol in a blood serum sample obtained by the method of the present invention shown in Example 4 or the control method using a reagent not containing an organic silicon compound of the present invention and the results obtained by the precipitation method, wherein A shows the correlation for the control method and B shows the correlation for the method of the present invention.
    • DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS
  • The method of the present invention comprises assaying lipid using a known reagent for assaying lipids in the presence of an organic silicon compound.
  • Silicones and their derivatives can be given as the organic silicon compound in the present invention. The silicones are the polymers which have organic groups such as an alkyl group or aryl group. The polymers comprise —(Si—O)n—, which is generally called polysiloxane, the recurrence 6structure of siloxane unit which consists of a silicon atom bonded with an oxygen atom. Properties of silicones differ according to the molecular structure. Viscosity, volatility, and other properties vary according to the degree of polymerization, types of side chains, the degree of crosslinking, and the like. There are liquid silicones, greasy silicones, rubbery silicones, and resinous silicones. These silicones and their derivatives are commercially available under classification names of silicone, high polymerization silicone, cyclic silicone, alkyl silicone, silicone-containing surfactant, modified silicone oil, and the like. The modified silicone oil is the silicone oil to which an organic group is added. According to the added organic group, the modified silicone oil is classified as an amino modified silicone oil, epoxy modified silicone oil, carboxyl modified silicone oil, polyether modified silicone oil, alkyl modified silicone oil, or the like. According to the structure, the modified silicone oil is classified as a side chain silicone oil, both terminal silicone oil, one terminal silicone oil, and side chain both terminal silicone oil. These silicones and derivatives may be used either individually or in combination of two or more in achieving the object of the present invention. Manufacturers publish catalogues describing properties and the like of their organic silicon products. Specific organic silicon compounds to be used may be selected by referring to these catalogues.
  • In measuring the target lipid, the organic silicon compound of the present invention may be either added simultaneously with the sample and the reagent for assaying the target lipid or mixed with the sample before adding the reagent for assaying the target lipid. Alternatively, the target lipid may be assayed by first preparing a mixture of the sample and a part of the reagent for assaying the target lipid and adding to the mixture the remaining portion of the reagent containing the organic silicon compound of the present invention.
  • There are no specific limitations to the method of detecting the target lipid after the addition of the reagent for assaying the target lipid. For example, spectrophotometric analysis using a combination of a peroxidase and a chromogen and a method of directly detecting a coenzyme and hydrogen peroxide can be given.
  • The amount of the organic silicon compound used for the sample in the present invention varies according to the type of the lipid to be assayed, the properties of the sample, the type of the reagent used, the presence or absence of the later-described surfactant or glycerol, or the amount of the surfactant or glycerol, and the like. Although optimum conditions should be selected by experiment, generally used amount of the organic silicon compound is about 0.0001-5 mass % (hereinafter simply referred to as “%”), and more preferably about 0.001-5%.
  • It is preferable to apply the above-described direct method to the present invention, that is, it is preferable to use the organic silicon compound of the present invention in combination with the reagent for the direct method. When used in combination with a surfactant which does not dissolve lipoproteins (Japanese Patent No. 2799835) or a surfactant having lipoprotein selectivity (Japanese Patent Application Laid-open Publication No. 056395/1999), for example, the organic silicon compound of the present invention can enhance the properties of these surfactants.
  • In addition, it is possible to emulsify the organic silicon compound of the present invention by adding a surfactant, glycerol, and the like to adjust the water solubility.
  • As the surfactant, any of anionic surfactants, nonionic surfactants, cationic surfactants, and ampholytic surfactants may be used without specific limitations. Examples include alkyl ether carboxylates, salts of N-acylamino acid, alkyl phosphates, N-acyl taurates, sulfonates, alkyl sulfates, polyoxyethylene alkyl ether sulfates, acetic acid betaines, imidazolines, alkyl ammonium salts, amide amines, polyhydric alcohol fatty acid esters, alkyl glyceryl ethers and their fatty acid esters, propylene glycol fatty acid esters, glycerides, polyglycerides, polyoxyethylene glycerides, sorbitan fatty acid esters, polyoxysorbitan fatty acid esters, polyoxyethylene sorbit fatty acid esters, polyoxyethylene lanolins, polyoxyethylene lanolin alcohols, polyoxyethylene bees wax derivatives, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyethylene sterols, polyoxyethylene hydrogenated sterols, polyethylene glycol fatty acid esters, polyoxyethylene alkyl ethers, polyoxyethylene polyoxypropylene alkyl ethers, polyoxyethylene polyoxypropylene condensates of ethylenediamine, polyoxyethylene alkylphenyl ethers, polyoxyethylene alkyl amines, sucrose fatty acid esters, polyoxyethylene fatty acid amides, polyoxyethylene alkylphenyl formaldehyde condensates, polyoxyethylene alkyl ether phosphoric acid, salts of polyoxyethylene alkyl ether phosphoric acid, and the like.
  • These surfactants may be added to the assay system either individually or in combination of two or more. The combination and amount of these surfactants vary according to the type of silicones and their derivatives, the type of surfactant used, and the like. Although optimum conditions should be selected by experiment, generally used concentration of the surfactant in the assay system is about 0.0001-5%, and more preferably about 0.001-5%.
  • In addition to the surfactant, polymer emulsifying agents such as an acrylic acid-alkyl methacrylate copolymer and carboxy vinyl polymer, organic solvents such as ethanol, silicones and their derivatives not adversely affecting the assay specificity, and the like can be used in adjusting the water solubility.
  • The lipid to be assayed by the method of the present invention may be any lipid present in the living body, and particularly preferable lipids are those forming lipoproteins such as cholesterols, triglycerides, and phospholipids.
  • Any enzyme having the target lipid as the substrate can be used in assaying the lipid in the method of the present invention. Enzymes commonly used for assaying cholesterols, triglycerides, and phospholipids described in Outline of Clinical Diagnosis Method, the 30th edition, (Kanehara and Co., Ltd., 1993), for example, can be used in the present invention and are included in the scope of the present invention.
  • When cholesterols are assayed among these lipids, enzymes commonly used for assaying cholesterols such as cholesterol dehydrogenase, cholesterol oxidase, and cholesterol esterase can be used without a limitation. These enzymes may be those originating from microorganisms, animals, or plants or may be those prepared by a genetic engineering technique. Either chemically modified or unmodified enzymes can be used.
  • These enzymes may be optionally used in combination with a coenzyme, a detecting enzyme or dyeing agent, or the like. As the coenzyme, nicotine amide adenine dinucleotide and the like can be given. As the detecting enzyme, peroxidase and the like can be given. As the dyeing agent, Trinder reagent, aminoantipyrine, and the like can be given.
  • The detecting enzymes may be used either individually or in combination of two or more. The amount used differs according to the enzymes. Although not specifically limited, the enzyme in the amount of 0.001-100 unit/mL, and preferably 0.1-100 unit/mL, is used.
  • The method of the present invention can be advantageously carried out by using a reagent for assaying lipid prepared by appropriately formulating the above-described organic silicon compound, enzyme for assaying lipid, dyeing agent, coenzyme, and the like. As required, reagents having affinity with specific lipoproteins, including other enzymes such as catalase, salts, pH adjusting buffering agents, surfactants, antiseptic agents, proteins such as albumin, antibodies, antibiotics, saponins, lectins, and polyanions, can be added to the extent that the assay specificity is not adversely affected and the specific lipoproteins are not aggregated.
  • As the buffering agent, any buffering agent such as Good's. buffer, phosphoric acid, Tris buffer, and phthalate may be used inasmuch as the buffering agent can establish buffering conditions of pH of the reaction solution in the range of 4-10. Although not specifically limited, the amount in the range of 0.0005-2 mol/L, and preferably of 0.01-1 mol/L, is applicable. In practice, optimum conditions should be selected by experiment in due consideration to the properties of the enzyme used, other components contained in the reagent, and the like.
  • Specific examples of the reagent for assaying lipid for advantageously carrying out the method of the present invention are given below.
  • (HDL-Cholesterol Assay Reagent)
      • (1) Organic silicon compound
      • (2) Cholesterol esterase
      • (3) Cholesterol oxidase
      • (4) Peroxidase
      • (5) Dyeing agent (4-aminoantipyrine and disulfobutyl metatoluidine, etc.)
        • A surfactant having lipoprotein selectivity and other additives may be optionally added.
          (LDL-Cholesterol Assay Reagent)
          (First Reagent)
      • (1) Organic silicon compound
      • (2) Cholesterol esterase
      • (3) Cholesterol oxidase
      • (4) Peroxidase
      • (5) Either one of two compounds generating a color by combination (e.g. 4-aminoantipyrine)
        • A surfactant having lipoprotein selectivity and other additives may be optionally added.
          (Second Reagent)
      • (6) The other of two compounds generating a color by combination (e.g. disulfobutylmetatoluidine)
      • (7) Surfactant with low lipoprotein selectivity
    EXAMPLES
  • The present invention will be described in more detail by way of Examples which should not be construed as limiting the present invention.
    • Example 1
  • The effect of the present invention was confirmed using HDL and LDL fractions prepared by ultracentrifugation as the samples. The reagent with the following formulation was used for assaying cholesterols in the HDL and LDL fractions.
    (First reagent)
    PIPES buffer solution (pH 6.5)  50 mmol/L
    4-Aminoantipyrine 0.5 mmol/L
    (Second reagent)
    PIPES buffer solution (pH 6.5)  50 mmol/L
    Cholesterol esterase   1 unit/mL
    Cholesterol oxidase   1 unit/mL
    Disulfobutylmetatoluidine 1.0 mmol/L
    Peroxidase   5 unit/mL
    Organic silicon compound 1%
    (all manufactured by Nippon
    Unicar Co., Ltd.)
  • Hitachi 7170 automatic analyzer was used. 240 μL of the first reagent was added to 2.4 μL of the sample. Five minutes later, 80 μL of the second reagent was added. Absorbance at a wavelength of 600 nm was measured immediately before the addition of the second reagent and 5 minutes thereafter. The difference of the two measurements was regarded as the absorbance of the sample. As a control, a reagent which contains 1% Triton X-100 having low lipoprotein selectivity instead of the organic silicon compound of the present invention was used as the second reagent.
  • Relative sample absorbances measured using reagents containing a different organic silicon compound for each as the second reagents were determined assuming the absorbance of the sample using the second reagent containing the Triton X-100 as 100. The ratio of the relative sample absorbance for LDL to the relative sample absorbance for HDL was calculated. The results are shown in Table 1.
    TABLE 1
    Relative Relative Ratio of relative
    absorbance absorbance absorbance
    Added components for HDL for LDL (LDL/HDL)
    Organic silicon 23 1 0.04
    compound 1
    (NUC-Silicon L7002)
    Organic silicon 94 9 0.10
    compound 2
    (NUC-Silicon L7604)
    Organic silicon 49 15 0.31
    compound 3
    (NUC-Silicon FZ2118)
    Organic silicon 14 7 0.50
    compound 4
    (NUC-Silicon FZ2162)
    Organic silicon 49 16 0.33
    compound 5
    (NUC-Silicon FZ2163)
    Surfactant (Triton X-100) 100 100 1.00
  • The LDL/HDL ratio of the relative absorbance when measured by using the second reagents containing the organic silicon compounds of the present invention was in the range of 0.04-0.5. The results indicate that the organic silicon compound of the present invention established special conditions under which the reaction between cholesterols in HDL and enzymes is predominant over the reaction between cholesterols in LDL and enzymes.
    • Example 2
  • The effect of the present invention was confirmed using 20 serum samples containing lipoproteins. Reagents with the following formulation were used for assaying.
    (First reagent)
    Bis-Tris buffer solution (pH 6.0)   50 mmol/L
    Cholesterol oxidase   1 unit/mL
    Peroxidase 1.25 unit/mL
    Disulfobutylmetatoluidine  0.5 mmol/L
    Flufenamic acid  150 μmol/L
    (Second reagent)
    Bis-Tris buffer solution (pH 6)   50 mmol/L
    Cholesterol esterase  1.5 unit/mL
    (Asahi Kasei Corporation)
    4-Aminoantipyrine  1.0 mmol/L
    Emulgen B-66  1.5%
    Organic silicon compound 0.001%
    (NUC-Silicon L720 manufactured by
    Nippon Unicar Co., Ltd.)
  • Hitachi 7170 automatic analyzer was used. 240 μL of the first reagent was added to 2.4 μL of the sample. Five minutes later, 80 μL of the second reagent was added. Absorbance at 600 nm wavelength was measured immediately before the addition of the second reagent and 5 minutes after the addition of the second reagent, to determine the HDL cholesterol concentration from the difference in the absorbance values (Two point method). A control serum with a known concentration was used as a calibration substance. As a control, a reagent not containing the organic silicon compound of the present invention was used as the second reagent.
  • At the same time, the HDL cholesterol concentration in the serum sample was determined using a commercially available precipitation reagent kit (HDL-C. 2 kit manufactured by Daiichi Pure Chemicals Co., Ltd.). The correlation coefficients and regression formula were compared, taking the value of the reagent in the precipitation method as X axis and the measured value in Examples as Y axis. The results are shown in Table 2 and FIG. 1.
    TABLE 2
    Unit: mg/dL
    Method of
    Precipitation the present
    Sample method Control invention
     1 83.2 81.4 84.4
     2 83.2 75.2 77.4
     3 72.7 70.4 71.3
     4 69.8 64.0 64.7
     5 68.1 67.6 68.3
     6 68.3 65.5 66.3
     7 62.3 60.0 60.8
     8 61.1 59.0 59.1
     9 56.9 56.2 56.5
    10 54.4 49.3 49.2
    11 52.7 51.8 53.2
    12 52.3 52.5 52.6
    13 49.0 48.0 48.4
    14 45.6 48.1 48.1
    15 43.3 40.9 41.1
    16 39.8 39.8 39.9
    17 39.5 41.3 40.7
    18 32.3 33.0 32.7
    19 32.2 33.8 33.5
    20 66.9 68.2 68.3
    Correlation — 0.989 0.989
    coefficient
    Slope — 0.891 0.935
    Intercept — 4.8 2.8
  • The results measured by using the second reagent containing the organic silicon compound of the present invention exhibited improved slope and intercept as compared with the results measured by using the second reagent not containing the organic silicon compound of the present invention. This indicates that the organic silicon compound of the present invention established specific conditions under which the reaction between cholesterols in HDL and enzymes is predominant over the reaction between cholesterols in LDL and enzymes, whereby the characteristics of the surfactant having lipoprotein selectivity was further improved.
    • Example 3
  • The effect of the present invention was confirmed in the same condition as in Example 2 except that 26 serum samples containing lipoproteins were used as the samples and NET-SG-60A (Example 3A) or NET-SG-60C (Example 3B) (both at a concentration of 0.05%, manufactured by Nihon Surfactant Kogyo KK.) was used as the organic silicon compound of the present invention in the second reagent. The results are shown in Table 3 and FIG. 2.
    TABLE 3
    Unit: mg/dL
    Method of the
    present invention
    Precipitation Example Example
    Sample method Control 3A 3B
     1 44.5 47.8 46.7 47.0
     2 49.3 51.1 50.9 51.1
     3 48.8 51.1 51.0 50.9
     4 69.7 72.4 72.7 73.6
     5 67.2 66.9 67.9 67.5
     6 66.4 69.1 69.1 69.1
     7 40.3 42.2 42.2 42.2
     8 28.6 32.4 30.8 30.5
     9 45.3 47.9 46.6 46.6
    10 46.8 48.2 48.1 48.2
    11 41.7 44.1 43.3 43.0
    12 41.1 45.0 42.7 43.6
    13 55.6 59.2 58.6 59.2
    14 52.6 56.2 55.3 56.1
    15 62.2 62.2 63.0 62.3
    16 32.7 35.9 34.8 35.0
    17 48.2 48.3 48.5 49.2
    18 47.4 49.2 49.6 49.0
    19 41.1 45.1 45.0 45.0
    20 53.3 54.8 54.2 54.3
    21 44.0 46.0 45.8 45.9
    22 75.3 78.2 79.5 80.1
    23 59.4 61.7 60.5 61.2
    24 37.1 39.7 39.3 39.6
    25 50.6 55.0 53.0 53.5
    26 36.9 40.9 40.4 40.3
    Correlation — 0.995 0.997 0.996
    coefficient
    Slope — 0.963 1.006 1.015
    Intercept — 4.3 1.8 1.5
  • The results measured by using the second reagent containing the organic silicon compound of the present invention exhibited improved slope and intercept as compared with the results measured by using the second reagent not containing the organic silicon compound of the present invention. This indicates that the organic silicon compound of the present invention established specific conditions under which the reaction between cholesterols in HDL and enzymes is predominant over the reaction between cholesterols in LDL and enzymes, whereby the characteristics of the surfactant having lipoprotein selectivity was further improved.
    • Example 4
  • The effect of the present invention was confirmed in the same condition as in Example 2 except that 30 serum samples containing lipoproteins were used as the samples and KF-700 (0.08%, manufactured by Shin-Etsu Chemical Co., Ltd.) was used as the organic silicon compound of the present invention in the second reagent. The results are shown in Table 4 and FIG. 3.
    TABLE 4
    Precipitation Method of the
    Sample method Control present invention
     1 98.6 98.7 98.2
     2 95.0 94.5 95.0
     3 87.4 87.9 89.4
     4 84.0 84.7 84.5
     5 80.4 82.6 81.8
     6 76.6 79.0 79.2
     7 74.2 76.6 76.1
     8 71.8 74.6 74.1
     9 69.2 70.6 70.0
    10 63.6 67.6 67.4
    11 60.0 63.8 64.2
    12 60.8 64.7 63.9
    13 59.8 63.2 62.9
    14 58.6 60.9 61.3
    15 55.8 59.7 59.2
    16 55.8 60.0 59.1
    17 54.4 58.3 57.1
    18 52.0 56.3 54.6
    19 49.0 53.8 52.8
    20 48.6 49.5 48.8
    21 45.0 48.2 47.5
    22 43.4 47.1 46.6
    23 45.0 46.8 46.0
    24 44.6 47.0 45.8
    25 42.0 44.0 42.9
    26 41.8 43.0 42.0
    27 38.0 42.3 40.9
    28 38.4 41.1 39.9
    29 37.0 38.5 37.2
    30 35.0 37.0 36.0
    Correlation coefficient — 0.997 0.997
    Slope — 0.963 0.988
    Intercept — 4.7 2.7
  • The results measured by using the second reagent containing the organic silicon compound of the present invention exhibited improved slope and intercept as compared with the results measured by using the second reagent not containing the organic silicon compound of the present invention. This indicates that the organic silicon compound of the present invention established specific conditions under which the reaction between cholesterols in HDL and enzymes is predominant over the reaction between cholesterols in LDL and enzymes, whereby the characteristics of the surfactant having lipoprotein selectivity was further improved.
    • Example 5
  • The effect of the present invention was confirmed in the same condition as in Example 2 except that 20 serum samples containing lipoproteins were used as the samples and the organic silicon compounds shown in Table 5 were used in the second reagent. In Table 5, the organic silicon compounds of Examples 5A-5D were used for formulating the second reagent after dissolving these compounds in ethanol to a concentration of 10%. The organic silicon compounds of Examples 5E and 5F were used for formulating the second reagent after dissolving and mixing these compounds in ethanol together with SH8400 (modified silicone oil manufactured by Dow Corning Toray Silicone Co., Ltd.) to a respective concentration of 10%. The results are shown in Table 6.
    TABLE 5
    Example Organic silicon compound*
    5A BY11-030(0.03%)
    5B BY22-008M(0.05%)
    5C SH-244(0.03%)
    5D SH-245(0.05%)
    5E DC345(0.02%)
    5F SH200C-2cs(0.02%)

    *All manufactured by Dow Corning Toray Silicone Co., Ltd.
  • TABLE 6
    Unit: mg/dL
    Precipitation Method of the present invention
    Sample method Control Example 5A Example 5B Example 5C Example 5D Example 5E Example 5F
     1 90.4 92.0 93.0 94.5 93.2 94.7 93.0 92.7
     2 81.4 83.1 83.1 84.3 82.8 82.8 85.9 83.5
     3 77.9 81.5 82.6 82.0 82.2 82.6 82.8 82.9
     4 74.4 77.9 78.2 79.2 78.5 79.2 78.5 78.0
     5 72.0 72.9 74.0 76.0 73.1 74.2 75.0 74.2
     6 69.9 70.8 71.1 71.4 71.1 71.9 71.4 70.7
     7 68.0 67.2 68.8 69.3 68.6 69.2 69.6 68.4
     8 65.4 70.4 70.3 71.0 69.6 71.8 70.5 69.9
     9 65.3 66.7 66.8 67.1 66.1 67.9 68.2 67.2
    10 59.9 62.8 62.4 63.3 62.7 63.6 62.6 62.0
    11 58.7 60.7 60.6 60.9 61.3 61.7 60.7 60.4
    12 57.9 61.2 61.6 62.1 61.2 61.6 62.0 61.6
    13 56.2 58.5 57.1 57.8 57.6 59.1 58.6 57.4
    14 54.0 55.6 55.6 57.3 56.3 55.7 56.7 55.6
    15 52.7 55.3 55.4 55.5 54.9 55.7 55.6 55.3
    16 51.8 52.1 52.4 52.7 52.6 53.2 53.1 52.4
    17 50.0 51.1 52.1 52.4 50.5 52.0 51.7 52.1
    18 49.4 52.3 52.5 51.9 51.7 52.3 52.0 52.3
    19 43.0 46.1 44.7 44.9 45.5 45.4 44.8 44.2
    20 41.1 43.9 43.2 44.0 43.4 43.7 43.8 43.5
    Correlation — 0.995 0.996 0.996 0.996 0.996 0.997 0.996
    coefficient
    Slope — 0.989 1.021 1.038 1.017 1.029 1.037 1.023
    Intercept — 2.81 0.99 0.54 1.15 1.15 0.56 0.82
  • The results measured by using the second reagent containing the organic silicon compound of the present invention exhibited particularly improved intercept as compared with the results measured by using the second reagent not containing the organic silicon compound of the present invention. This indicates that the organic silicon compound of the present invention established specific conditions under which the reaction with cholesterols in HDL is predominant over the reaction between cholesterols in LDL and enzymes, whereby the characteristics of the surfactant having lipoprotein selectivity was further improved.
  • Industrial Applicability
  • Lipids in specific fractions (e.g. cholesterols) can be quantitatively determined efficiently by a simple procedure without requiring a pretreatment such as centrifugation by using the method of the present invention. In addition, because the method allows specific determination by a simple method using a small amount of sample, the method can be applied to various types of automatic analyzers. The method is thus extremely useful in the field of clinical diagnosis. The high lipoprotein selectivity particularly improves the intercept and slope, providing an advantage of minute lipoprotein selectivity control.

Claims (13)

1-16. (canceled)
17. A method of assaying lipid, comprising assaying the lipid in blood components in the presence of an organic silicon compound.
18. The method according to claim 17, wherein the organic silicon compound is a silicone, a derivative of silicone or a combination thereof.
19. The method according to claim 18, wherein the silicone or the derivative of silicone is at least one member selected from the group consisting of high polymerization silicone, cyclic silicone, silicone-containing surfactant, and modified silicone oil.
20. The method according to claim 17, wherein the lipid component is a lipid contained in a specific lipoprotein.
21. The method according to claim 17, wherein the lipid component is a cholesterol, triglycerides, or phospholipid.
22. The method according to claim 20, wherein a lipid contained in the lipoprotein is detected by acting an enzyme on the lipoprotein, under conditions in which the organic silicon compound is present and a precipitation agent is not present.
23. The method according to claim 22, wherein the enzyme is acted on the lipid in a lipoprotein in the presence of a surfactant having lipoprotein selectivity.
24. A reagent for assaying lipids, comprising an organic silicon compound.
25. The reagent according to claim 24, wherein the organic silicon compound is a silicone, a derivative of silicone or a combination thereof.
26. The reagent according to claim 25, wherein the silicone or the derivative of silicone is at least one member selected from the group consisting of high polymerization silicone, cyclic silicone, silicone-containing surfactant, and modified silicone oil.
27. The reagent according to claim 24, wherein the lipid component is a lipid contained in a specific lipoprotein.
28. The reagent according to claim 27, wherein the lipid component is a cholesterol, triglycerides, or phospholipid.
US11/066,168 2000-11-14 2005-02-28 Method of lipid assay and reagent for use therein Abandoned US20050142627A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US11/066,168 US20050142627A1 (en) 2000-11-14 2005-02-28 Method of lipid assay and reagent for use therein
US12/047,357 US20080166746A1 (en) 2000-11-14 2008-03-13 Method of lipid assay and reagent for use therein
US12/969,900 US20110287460A1 (en) 2000-11-14 2010-12-16 Method of lipid assay and reagent for use therein
US13/198,020 US20120178117A1 (en) 2000-11-14 2011-08-04 Method of lipid assay and reagent for use therein
US13/738,449 US20130164768A1 (en) 2000-11-14 2013-01-10 Method of lipid assay and reagent for use therein
US13/763,125 US20130210044A1 (en) 2000-11-14 2013-02-08 Method of lipid assay and reagent for use therein
US14/067,216 US20140051102A1 (en) 2000-11-14 2013-10-30 Method of lipid assay and reagent for use therein
US14/287,786 US20140287444A1 (en) 2000-11-14 2014-05-27 Method of lipid assay and reagent for use therein
US15/047,421 US20160209434A1 (en) 2000-11-14 2016-02-18 Method of lipid assay and reagent for use therein
US15/720,274 US20180038878A1 (en) 2000-11-14 2017-09-29 Method of lipid assay and reagent for use therein
US16/409,965 US20190331700A1 (en) 2000-11-14 2019-05-13 Method of lipid assay and reagent for use therein

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000346791 2000-11-14
JP2000-346791 2000-11-14
US10/416,166 US6979552B2 (en) 2000-11-14 2001-11-13 Method of lipid assay and reagent for use therein
PCT/JP2001/009899 WO2002040707A1 (en) 2000-11-14 2001-11-13 Method of lipid assay and reagent for use therein
US11/066,168 US20050142627A1 (en) 2000-11-14 2005-02-28 Method of lipid assay and reagent for use therein

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/416,166 Continuation US6979552B2 (en) 2000-11-14 2001-11-13 Method of lipid assay and reagent for use therein
PCT/JP2001/009899 Continuation WO2002040707A1 (en) 2000-11-14 2001-11-13 Method of lipid assay and reagent for use therein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/047,357 Continuation US20080166746A1 (en) 2000-11-14 2008-03-13 Method of lipid assay and reagent for use therein

Publications (1)

Publication Number Publication Date
US20050142627A1 true US20050142627A1 (en) 2005-06-30

Family

ID=18820611

Family Applications (12)

Application Number Title Priority Date Filing Date
US10/416,166 Expired - Lifetime US6979552B2 (en) 2000-11-14 2001-11-13 Method of lipid assay and reagent for use therein
US11/066,168 Abandoned US20050142627A1 (en) 2000-11-14 2005-02-28 Method of lipid assay and reagent for use therein
US12/047,357 Abandoned US20080166746A1 (en) 2000-11-14 2008-03-13 Method of lipid assay and reagent for use therein
US12/969,900 Abandoned US20110287460A1 (en) 2000-11-14 2010-12-16 Method of lipid assay and reagent for use therein
US13/198,020 Abandoned US20120178117A1 (en) 2000-11-14 2011-08-04 Method of lipid assay and reagent for use therein
US13/738,449 Abandoned US20130164768A1 (en) 2000-11-14 2013-01-10 Method of lipid assay and reagent for use therein
US13/763,125 Abandoned US20130210044A1 (en) 2000-11-14 2013-02-08 Method of lipid assay and reagent for use therein
US14/067,216 Abandoned US20140051102A1 (en) 2000-11-14 2013-10-30 Method of lipid assay and reagent for use therein
US14/287,786 Abandoned US20140287444A1 (en) 2000-11-14 2014-05-27 Method of lipid assay and reagent for use therein
US15/047,421 Abandoned US20160209434A1 (en) 2000-11-14 2016-02-18 Method of lipid assay and reagent for use therein
US15/720,274 Abandoned US20180038878A1 (en) 2000-11-14 2017-09-29 Method of lipid assay and reagent for use therein
US16/409,965 Abandoned US20190331700A1 (en) 2000-11-14 2019-05-13 Method of lipid assay and reagent for use therein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/416,166 Expired - Lifetime US6979552B2 (en) 2000-11-14 2001-11-13 Method of lipid assay and reagent for use therein

Family Applications After (10)

Application Number Title Priority Date Filing Date
US12/047,357 Abandoned US20080166746A1 (en) 2000-11-14 2008-03-13 Method of lipid assay and reagent for use therein
US12/969,900 Abandoned US20110287460A1 (en) 2000-11-14 2010-12-16 Method of lipid assay and reagent for use therein
US13/198,020 Abandoned US20120178117A1 (en) 2000-11-14 2011-08-04 Method of lipid assay and reagent for use therein
US13/738,449 Abandoned US20130164768A1 (en) 2000-11-14 2013-01-10 Method of lipid assay and reagent for use therein
US13/763,125 Abandoned US20130210044A1 (en) 2000-11-14 2013-02-08 Method of lipid assay and reagent for use therein
US14/067,216 Abandoned US20140051102A1 (en) 2000-11-14 2013-10-30 Method of lipid assay and reagent for use therein
US14/287,786 Abandoned US20140287444A1 (en) 2000-11-14 2014-05-27 Method of lipid assay and reagent for use therein
US15/047,421 Abandoned US20160209434A1 (en) 2000-11-14 2016-02-18 Method of lipid assay and reagent for use therein
US15/720,274 Abandoned US20180038878A1 (en) 2000-11-14 2017-09-29 Method of lipid assay and reagent for use therein
US16/409,965 Abandoned US20190331700A1 (en) 2000-11-14 2019-05-13 Method of lipid assay and reagent for use therein

Country Status (10)

Country Link
US (12) US6979552B2 (en)
EP (1) EP1335026B1 (en)
KR (1) KR20040012678A (en)
CN (1) CN1313620C (en)
AT (1) ATE373829T1 (en)
AU (1) AU2002212760A1 (en)
CA (1) CA2428686A1 (en)
DE (1) DE60130576T2 (en)
MX (1) MXPA03004206A (en)
WO (1) WO2002040707A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265939A1 (en) * 1999-06-21 2004-12-30 Daiichi Pure Chemicals Co., Ltd. Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
US20090130696A1 (en) * 2006-05-12 2009-05-21 Lindy Murphy HDL Cholesterol Sensor Using Selective Surfactant
US20090188812A1 (en) * 2006-05-12 2009-07-30 John Morton Broughall Cholesterol Sensor

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313620C (en) * 2000-11-14 2007-05-02 第一化学药品株式会社 Method of lipid assay and reagent for use therein
ES2335658T3 (en) * 2002-10-16 2010-03-31 Kyowa Medex Co., Ltd. METHOD AND REAGENT THAT ALLOWS MEASURING CHOLESTEROL IN THE HIGH DENSITY PROTEIN LIPO.
MXPA05005708A (en) * 2002-11-27 2005-07-26 Daiichi Pure Chemicals Co Ltd Method of measuring lipid in specific lipoprotein.
JP4647927B2 (en) * 2004-03-31 2011-03-09 デンカ生研株式会社 Multiple determination of cholesterol in low density lipoprotein
CN104048955A (en) * 2013-03-11 2014-09-17 南京澳林生物科技有限公司 High density lipoprotein cholesterol detection kit
ES2783857T3 (en) 2015-06-19 2020-09-18 Shino Test Corp Substrate solution to measure lipase activity and method and reagent to measure lipase activity in a sample
CN109856132A (en) * 2019-01-22 2019-06-07 杭州联晟生物科技有限公司 It is a kind of for detecting the test card and preparation method thereof of sample middle-high density lipoprotein cholesterol

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689309A (en) * 1985-09-30 1987-08-25 Miles Laboratories, Inc. Test device, method of manufacturing same and method of determining a component in a sample
US4826761A (en) * 1985-07-09 1989-05-02 Fuji Photo Film Co, Ltd. Multilayer analytical element for analysis of cholesterol
US4892815A (en) * 1986-10-29 1990-01-09 Boehringer Mannheim Gmbh Process and reagent for the specific determination of the cholesterol of the HDL fraction
US4907133A (en) * 1988-10-26 1990-03-06 Nath Guenther Illumination device with a light guide of a liquid-filled plastic flexible tube
US5099053A (en) * 1989-05-26 1992-03-24 Shin-Etsu Chemical Co., Ltd. Fluorine-containing organic silicon compounds and a manufacturing method thereof
US5166051A (en) * 1990-08-08 1992-11-24 Genesis Labs, Inc. Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes
US6142514A (en) * 1996-09-20 2000-11-07 Daicel Chemical Industries, Ltd. Air bag gas inflator
US6632677B1 (en) * 1998-09-14 2003-10-14 Daiichi Pure Chemicals Co., Ltd. Air shutoff agent for aqueous reagent and aqueous specimen, and method for storing aqueous reagent and aqueous specimen with stability
US20040053350A1 (en) * 2000-11-14 2004-03-18 Mitsuaki Yamamoto Method of lipid assay and reagent for use therein
US6818414B1 (en) * 1999-06-21 2004-11-16 Daiichi Pure Chemicals Co., Ltd. Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894844A (en) * 1974-01-31 1975-07-15 American Cyanamid Co Simultaneous determination of triglycerides, cholesterol and phospholipids
JPS56155853A (en) 1980-05-02 1981-12-02 Kobayashi Seiyaku Kk Method for measuring cholesterol in blood
IL79945A (en) 1986-09-04 1991-06-10 I D L International Diagnostic Method for the quantitative determination of total cholesterol in blood
JPH0616720A (en) 1992-07-01 1994-01-25 Fujitsu Ltd Composition for plastic optical waveguide and production of plastic optical waveguide
JP3107474B2 (en) 1993-02-17 2000-11-06 国際試薬株式会社 Method for quantification of components in lipoprotein fraction
JP2653755B2 (en) 1994-03-08 1997-09-17 協和メデックス株式会社 Determination of cholesterol in high density lipoprotein
JP2600065B2 (en) 1994-03-08 1997-04-16 協和メデックス株式会社 Determination of cholesterol in high density lipoprotein
CN1145095A (en) * 1994-03-30 1997-03-12 普罗格特-甘布尔公司 Laundry detergent bars containing fabric softening clay
JP2799835B2 (en) 1995-01-31 1998-09-21 第一化学薬品株式会社 How to determine cholesterol
JP3091230B2 (en) * 1995-03-20 2000-09-25 協和メデックス株式会社 Determination of cholesterol in low-density lipoprotein or ultra-low-density lipoprotein
JP3614514B2 (en) 1995-06-21 2005-01-26 国際試薬株式会社 Method for quantifying cholesterol in high-density lipoprotein fraction and reagent kit for quantification
JP3694121B2 (en) 1995-08-31 2005-09-14 株式会社三菱化学ヤトロン Composition and method for specific measurement of HDL cholesterol
EP0852012B1 (en) * 1996-05-01 2006-07-26 Dade Behring Marburg GmbH Chemiluminescent compositions and their use in the detection of hydrogen peroxide
JP3193634B2 (en) * 1996-05-29 2001-07-30 第一化学薬品株式会社 LDL cholesterol determination method
JP3251304B2 (en) 1997-06-25 2002-01-28 国際試薬株式会社 Method for analyzing substances in biological sample components and reagents used in the method
JPH1156395A (en) 1997-08-27 1999-03-02 Dai Ichi Pure Chem Co Ltd Determination of cholesterol
JP2000116400A (en) 1998-10-09 2000-04-25 Ttk Kenkyusho:Kk Quantitative analysis of cholesterol in lipoprotein
JP2000325097A (en) * 1999-05-21 2000-11-28 Showa Denko Kk Method and reagent for measuring lipoprotein cholesterol

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826761A (en) * 1985-07-09 1989-05-02 Fuji Photo Film Co, Ltd. Multilayer analytical element for analysis of cholesterol
US4689309A (en) * 1985-09-30 1987-08-25 Miles Laboratories, Inc. Test device, method of manufacturing same and method of determining a component in a sample
US4892815A (en) * 1986-10-29 1990-01-09 Boehringer Mannheim Gmbh Process and reagent for the specific determination of the cholesterol of the HDL fraction
US4907133A (en) * 1988-10-26 1990-03-06 Nath Guenther Illumination device with a light guide of a liquid-filled plastic flexible tube
US5099053A (en) * 1989-05-26 1992-03-24 Shin-Etsu Chemical Co., Ltd. Fluorine-containing organic silicon compounds and a manufacturing method thereof
US5166051A (en) * 1990-08-08 1992-11-24 Genesis Labs, Inc. Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes
US6142514A (en) * 1996-09-20 2000-11-07 Daicel Chemical Industries, Ltd. Air bag gas inflator
US6632677B1 (en) * 1998-09-14 2003-10-14 Daiichi Pure Chemicals Co., Ltd. Air shutoff agent for aqueous reagent and aqueous specimen, and method for storing aqueous reagent and aqueous specimen with stability
US6818414B1 (en) * 1999-06-21 2004-11-16 Daiichi Pure Chemicals Co., Ltd. Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
US20040265939A1 (en) * 1999-06-21 2004-12-30 Daiichi Pure Chemicals Co., Ltd. Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
US20050009125A1 (en) * 1999-06-21 2005-01-13 Daiichi Pure Chemicals Co., Ltd. Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
US20040053350A1 (en) * 2000-11-14 2004-03-18 Mitsuaki Yamamoto Method of lipid assay and reagent for use therein

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265939A1 (en) * 1999-06-21 2004-12-30 Daiichi Pure Chemicals Co., Ltd. Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
US20050009125A1 (en) * 1999-06-21 2005-01-13 Daiichi Pure Chemicals Co., Ltd. Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
US7335483B2 (en) 1999-06-21 2008-02-26 Daiichi Pure Chemicals Co., Ltd. Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
US20090226945A1 (en) * 1999-06-21 2009-09-10 Daiichi Pure Chemicals Co., Ltd. Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
US20090130696A1 (en) * 2006-05-12 2009-05-21 Lindy Murphy HDL Cholesterol Sensor Using Selective Surfactant
US20090188812A1 (en) * 2006-05-12 2009-07-30 John Morton Broughall Cholesterol Sensor

Also Published As

Publication number Publication date
EP1335026A4 (en) 2005-01-05
US20080166746A1 (en) 2008-07-10
US20190331700A1 (en) 2019-10-31
CA2428686A1 (en) 2002-05-23
MXPA03004206A (en) 2003-09-22
AU2002212760A1 (en) 2002-05-27
US20110287460A1 (en) 2011-11-24
DE60130576D1 (en) 2007-10-31
US20120178117A1 (en) 2012-07-12
US20160209434A1 (en) 2016-07-21
US20130164768A1 (en) 2013-06-27
ATE373829T1 (en) 2007-10-15
CN1474874A (en) 2004-02-11
US20140287444A1 (en) 2014-09-25
US20140051102A1 (en) 2014-02-20
DE60130576T2 (en) 2008-06-12
KR20040012678A (en) 2004-02-11
EP1335026A1 (en) 2003-08-13
US20040053350A1 (en) 2004-03-18
US20180038878A1 (en) 2018-02-08
US20130210044A1 (en) 2013-08-15
EP1335026B1 (en) 2007-09-19
US6979552B2 (en) 2005-12-27
WO2002040707A1 (en) 2002-05-23
CN1313620C (en) 2007-05-02

Similar Documents

Publication Publication Date Title
US20190331700A1 (en) Method of lipid assay and reagent for use therein
KR101394802B1 (en) Reagent for determination of quantity of small dense low-density lipoprotein
CN103952462B (en) The method and kit of quantification of small, dense LDL cholesterol
AU702445B2 (en) Method for determination of cholesterol in low-density lipoprotein or very low-density lipoprotein
US8163512B2 (en) Method for determination of cholesterol in small dense low-density lipoprotein
JP5548733B2 (en) Method and kit for quantifying small particle low specific gravity lipoprotein
JPWO2004048605A1 (en) Method for measuring lipids in specific lipoproteins
AU2324301A (en) Method and reagent for determination of cholesterol in remnant-like particles
CN111032880A (en) Method, reagent and kit for measuring cholesterol in low-density lipoprotein
CN103314113A (en) Method for quantification of remnant-like lipoprotein cholesterol and kit for same
JP3844058B2 (en) Lipid measuring method and reagent used therefor
US20140147869A1 (en) Method and Kit for Measuring Cholesterol in Low-Density Lipoproteins
US7348158B2 (en) Method of quantifying cholesterol in high density lipoprotein and reagent compositions
KR20190012168A (en) Method and Quantitative Reagent for Determination of Cholesterol in Triglyceride Rich-lipoprotein
JP4490389B2 (en) Lipid measuring method and reagent used therefor
JPH07155196A (en) Method for measuring biological component
AU677514B2 (en) Method of determining cholesterol in high-density lipoprotein
MXPA96005693A (en) Method for the determination of low-density cholesterol in a low-density lipoprotein or a very low-densi lipoprotein enuna

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION